Topics
- The effects of the shift from reference pricing to value based pricing in Europe
- The effects of healthcare reform on the balance of power between national and regional payers
- The implications of US and UK healthcare reform for the pharma industry as a whole
- Productive partnerships with patients and KOLs to help communicate value messages
- The relevance of corporate social responsibility and its role in meeting the needs of stakeholder
Who should Attend
Delegates from national payer organisations, pharmaceutical companies, patient advocacy groups and academics interested in health economics and other delegates from Health Economics, Pricing and Reimbursement, Patient Access, Government Affairs, KOL Management, Sales and Marketing, Corporate Strategy, Brand Management, Public Affairs, Regulatory Affairs, Contracts, Outcomes Research, Distribution, Health Policy and Communications.
